Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05689619 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)

Study acronym: SILMET
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 15, 2023 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Lead sponsor: Alessia Pellerino to A.O.U. Città della Salute e della Scienzav2 Show 4 more changesShow less
    • Primary completion date: Jan 1, 2025 to Sep 1, 2025
    • Start date: Jan 2, 2023 to Sep 1, 2023
    • Study sites: 5 to 6
    • Study completion date: Jan 1, 2027 to Sep 1, 2027
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).
Trial Details
NCT Number NCT05689619
Lead Sponsor A.O.U. Città della Salute e della Scienza
Conditions
(from sponsor)		 Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer
Related terms Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov